Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GE molecular diagnostics

This article was originally published in The Gray Sheet

Executive Summary

General Electric reaffirms its interest in supplementing imaging with in vitro diagnostics Oct. 1 with a three-year agreement with Eli Lilly to develop molecular assays that help target cancer therapies. The multiplexed tissue tests being developed at GE Healthcare and GE Global Research aim to identify protein and gene signatures to predict whether Eli Lilly's drugs will be effective. The collaboration follows the collapse of GE's planned buyout of part of Abbott's diagnostics business for $8 billion in July (1"The Gray Sheet" July 16, 2007, p. 3)

You may also be interested in...

GE And Abbott Walk Away From $8 Billion Diagnostics Deal

Abbott says it will continue to manage its core laboratory and point-of-care diagnostics business for the long-term following the collapse of an $8.13 billion deal to sell the unit to General Electric

ASH 2020: J&J/Legend’s Cilta-Cel Shines, But BMS/Bluebird’s Ide-Cel Is In First Place

Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.

The Race To Develop A COVID-19 Vaccine: mRNA Pioneers Lead The Way

Our updated graphic tracker of key developments from the leading vaccine candidates.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts